Videos

Dr Javier Pinilla-Ibarz leads the discussion on the role of targeted therapy over chemoimmunotherapy as a CLL therapeutic approach and shares NCCN Guidelines recommendations for the use of BTK inhibitors.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some social and cultural aspects that may contribute to hypoactive sexual desire disorder going untreated in women.

Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.

Sebastian Denison, RPh, BScPharm, said new developments are constantly being published for the use of low-dose naltrexone in patients with inflammatory and autoimmune diseases.

Although marketing may seem intimidating, pharmacy owners should jump in and discover what works best for their pharmacy.

Tyler Woods, PharmD, pharmacy district manager with VMC Buying Group, discussed how partnering together can help independent pharmacies obtain drugs at a lower cost.

Jen Diehl, CPA, discussed some common financial concerns for independent pharmacies and where she sees the landscape heading in the future.

Sachin Nagrani, MD, the medical director of Heal, discusses his predictions for the future as we continue to fight the COVID-19 pandemic.

Pharmacy technicians are continuing to prove their worth as pharmacies shift their focus to the future, according to Jessica Langley-Loep, executive director of education and advocacy at the National Healthcareer Association.

Tom Wheelwright, CPA, founder and CEO of WealthAbility, discussed his perspective on taxes and how pharmacies can use them to their advantage.

Pharmacy Development Services business coach Patrick Lott discussed the impacts that a positive culture and effective leadership can have both on employee satisfaction and patient outcomes.

Marci Strauss, PharmD, discussed how pharmacists are reacting to the ongoing shift toward performance-based reimbursement models.

Dan Benamoz, RPh, founder and executive chairman of PDS, and Chip Phillips, CEO, discussed their plans for the meeting and what they're focused on for the future of pharmacy.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some of the common practices for the treatment of hypoactive sexual desire disorder in women and men.

Sachin Nagrani, MD, the medical director of Heal, discusses what pharmacists should know about the Omicron variant and other variants popping up globally.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses whether hypoactive sexual desire disorder is associated with psychological and/or emotional components.

NVX-CoV2373 (Novavax) was found to provide 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial last year.

Anthony Perissinotti, PharmD, BCOP, explains potential scenarios requiring anti-CD20 monoclonal antibodies as a therapy for chronic lymphocytic leukemia.

Kirollos Hanna, PharmD, BCPS, BCOP, reviews the use of anti-CD20 monoclonal antibodies for treating chronic lymphocytic leukemia.

Lisa Nodzon, PhD, ARNP, AOCNP, and Javier Pinilla-Ibarz, MD, PhD, provide insight on NCCN guideline recommendations for molecular testing in CLL and discuss the prevalence of testing for cytogenetic abnormalities.

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown and a urologic surgeon, discusses hypoactive sexual desire disorder and the current treatments available for this medical condition.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how building resilience in the medicine supply chain will help bolster preparedness for what may arise during the COVID-19 pandemic and beyond.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses contributing factors leading to health care professionals experience of an erosion of trust in the medicine supply chain.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how drug shortages are related to medicine quality issues.

Ronald T. Piervincenzi, CEO of US Pharmacopeia (USP), discusses recent survey data demonstrating 90% of physicians had experienced an erosion of trust in the US supply chain’s ability to deliver safe, quality medicines.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, addresses how pharmacists can respond to questions patients may ask them about ketamine and other psychedelic treatments.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, explains how ketamine infusions work when administered in patients’ homes and what safety precautions would be taken by providers in this setting.

Data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded treatment offering that would include psychedelic medicines.